Agios Pharmaceuticals (AGIO) Other Non-Current Assets (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Other Non-Current Assets data on file, last reported at $9.7 million in Q2 2026.

• Quarterly Other Non-Current Assets rose 145.59% year-over-year to $9.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.7 million (up 145.59% YoY) and the FY2025 annual result came in at $3.9 million, down 16.79% from the prior year.
• Other Non-Current Assets rose to $9.7 million in Q2 2026, from $3.9 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $9.7 million in Q2 2026 to a low of $2.9 million in Q1 2022.
• A 5-year average of $4.3 million and a median of $4.0 million in 2022 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets slumped 94.79% — and 2026, when it soared 145.59%.
• Tracing AGIO's Other Non-Current Assets over 5 years: stood at $4.0 million in 2022, then advanced by 2.55% to $4.1 million in 2023, then gained by 16.44% to $4.7 million in 2024, then slipped by 16.79% to $3.9 million in 2025, then soared by 146.27% to $9.7 million in 2026.
• The last three Other Non-Current Assets figures came in at $9.7 million (Q2 2026), $3.9 million (Q1 2026), and $3.9 million (Q4 2025), per Business Quant data.